Asabys Announces the Closing of €180M Oversubscribed Sabadell Asabys II Fund - Asabys Partners

READ THIS NEWS IN SPANISH

New fund is investing across the board in life sciences to improve patient outcomes

Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech and digital health that provide a clear benefit for patients

Asabys Partners announced today the successful final close of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII II) with total commitments of €180 million ($200M), exceeding its initial target of €150 million. SAHII II will invest in 12 to 15 companies in line with Asabys’ core strategy of funding biopharma, medical device and digital health companies that develop novel solutions for unmet medical needs building on solid scientific evidence and a clear benefit for patients. SAHII II welcomed new US and international investors in addition to investors from its previous fund, SAHII I, which closed with €117 million in commitments.

The SAHII II fund’s first closing was announced in January 2023 and since then has already invested in five companies: deepull, Orikine Bio, Gradient Denervation Technologies, ALLOX and Augustine Therapeutics.

“We value the support and confidence from our new and existing investors who have joined us for our second fund and share our commitment to global life science innovation and emerging scientific developments in AI, biology and new materials. Our experienced team and the track record we have built since our inception in 2018 provide us with a strong position to continue executing on our investment strategy,” commented Josep Sanfeliu, Founding and Managing Partner at Asabys.

“The successful and oversubscribed close of our SAHII II fund allows us to continue investing in the Spanish life sciences ecosystem, while strategically broadening our focus to Europe and other global markets. This new fund will enable us to back highly differentiated science and technology-driven companies developing new candidates that provide true benefits for patients,” added Clara Campàs, Founding and Managing Partner at Asabys.

Since its inception in 2018, Asabys has raised close to €300 million in assets under management, invested in 17 companies, with 3 exits to date. The team is composed of 11 professionals with deep scientific and technical expertise as well as years of track record investing in the industry, backed by a list of venture partners and advisors.